O. Lacombe

Localisation of drug permeability along the rat small intestine, using markers of the paracellular, transcellular and some transporter routes.

G. Houin, C. Boursier-Neyret, J. Woodley, 2004, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

Validation of a liquid chromatography-mass spectrometry method to assess the metabolism of dextromethorphan in rat everted gut sacs.

G. Houin, J. Woodley, O. Lacombe, 2005, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Design, Synthesis, and Evaluation of a Novel Series of Indole Sulfonamide Peroxisome Proliferator Activated Receptor (PPAR) α/γ/δ Triple Activators: Discovery of Lanifibranor, a New Antifibrotic Clinical Candidate.

J. Binet, J. Junien, Stéphanie Ferry, 2018, Journal of medicinal chemistry.

The pan-PPAR agonist lanifibranor reduces development of lung fibrosis and attenuates cardiorespiratory manifestations in a transgenic mouse model of systemic sclerosis

D. Abraham, C. Denton, I. Konstantinova, 2021, Arthritis Research & Therapy.

MPS VI associated ocular phenotypes in an MPS VI murine model and the therapeutic effects of odiparcil treatment.

E. Entchev, A. Roussey, Haoyue Zhang, 2021, Molecular genetics and metabolism.

Oral treatment for mucopolysaccharidosis VI: Outcomes of the first phase IIa study with odiparcil

C. Hendriksz, D. Hughes, E. Teles, 2021, Journal of inherited metabolic disease.

The Perfused Everted Intestinal Segment of Rat

Peggy Gandia, Georges Houin, G. Houin, 2004, Arzneimittelforschung.

Odiparcil, a potential glycosaminoglycans clearance therapy in mucopolysaccharidosis VI—Evidence from in vitro and in vivo models

E. Entchev, J. Junien, A. Bouchot, 2020, PloS one.

In vitro primary human and animal cell-based blood-brain barrier models as a screening tool in drug discovery.

Alain Pruvost, Henri Bénech, E. Thévenot, 2011, Molecular pharmaceutics.